Robert Jeraj Selected Research

copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)

1/2016	An imaging-based computational model for simulating angiogenesis and tumour oxygenation dynamics.
7/2015	Predicting location of recurrence using FDG, FLT, and Cu-ATSM PET in canine sinonasal tumors treated with radiotherapy.
4/2015	Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
6/2014	Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
10/2012	An imaging-based stochastic model for simulation of tumour vasculature.
10/2012	Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx.
10/2012	Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.
8/2011	Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling.
10/2010	Feasibility and sensitivity study of helical tomotherapy for dose painting plans.
10/2010	Feasibility of dose painting using volumetric modulated arc optimization and delivery.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Jeraj Research Topics

Disease

43	Neoplasms (Cancer) 01/2021 - 01/2003
14	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 05/2013
10	Hypoxia (Hypoxemia) 01/2016 - 08/2008
7	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2015
4	Melanoma (Melanoma, Malignant) 01/2022 - 01/2019
4	Disease Progression 01/2021 - 02/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 02/2012
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2009 - 05/2008
2	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 02/2014
2	Lymphoma (Lymphomas) 11/2020 - 09/2020
2	Circulating Neoplastic Cells 11/2020 - 01/2018
2	Hypertension (High Blood Pressure) 12/2016 - 02/2014
2	Squamous Cell Carcinoma of Head and Neck 04/2015 - 08/2011
2	Carcinoma (Carcinomatosis) 06/2014 - 11/2013
2	Sarcoma (Soft Tissue Sarcoma) 06/2014 - 11/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 03/2014 - 12/2011
2	Lung Neoplasms (Lung Cancer) 10/2013 - 02/2012
1	Colitis 01/2021
1	Hodgkin Disease (Hodgkin's Disease) 12/2020
1	Cytopenia 01/2018
1	Infections 01/2018
1	Granuloma 01/2017
1	Solitary Pulmonary Nodule 01/2017
1	Hemolytic Anemia 03/2014
1	Intestinal Perforation 02/2014
1	Neutropenia 02/2014
1	Oropharyngeal Neoplasms 10/2012
1	Bites and Stings (Sting) 07/2012
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2011
1	Leukemia 03/2011
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2010

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2013
11	copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)IBA 01/2016 - 03/2009
9	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 11/2013
5	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2016 - 12/2011
4	Bevacizumab (Avastin)FDA Link 04/2015 - 10/2012
3	FluoridesIBA 01/2021 - 12/2015
3	Axitinib (AG 013736)IBA 01/2018 - 07/2015
3	alovudineIBA 01/2018 - 11/2013
2	AntibodiesIBA 12/2020 - 01/2019
2	Prostate-Specific Antigen (Semenogelase)IBA 11/2020 - 12/2019
2	FluorineIBA 09/2020 - 01/2015
2	pembrolizumabIBA 01/2020 - 01/2019
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2018 - 12/2011
2	Sodium Fluoride (Ossin)FDA Link 08/2017 - 01/2015
2	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 04/2015
2	Pharmaceutical PreparationsIBA 12/2016 - 08/2010
2	Biological ProductsIBA 04/2015 - 11/2013
2	Sunitinib (Sutent)FDA Link 03/2014 - 12/2011
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 08/2013 - 01/2012
2	Oxygen (Dioxygen)IBA 10/2012 - 08/2011
2	NucleotidesIBA 05/2009 - 05/2008
2	rabacfosadineIBA 05/2009 - 05/2008
1	Amino Acids FDA Link 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	Dasatinib (BMS 354825)FDA Link 01/2021
1	Bispecific AntibodiesIBA 12/2020
1	Chimeric Antigen ReceptorsIBA 12/2020
1	enzalutamideIBA 11/2020
1	prostatic acid phosphataseIBA 12/2019
1	A-Form DNA (A-DNA)IBA 12/2019
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2019
1	VaccinesIBA 12/2019
1	Technetium Tc 99m MedronateIBA 01/2019
1	DNA VaccinesIBA 01/2019
1	ElectrolytesIBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	Androgen Receptors (Androgen Receptor)IBA 08/2017
1	NivolumabIBA 01/2017
1	Etoposide (VP 16)FDA LinkGeneric 01/2017
1	Deoxyglucose (2 Deoxy D glucose)IBA 12/2015
1	SodiumIBA 12/2015
1	Diacetyl (Biacetyl)IBA 04/2015
1	ZD4054IBA 02/2015
1	Temozolomide (Temodar)FDA LinkGeneric 02/2014
1	Monoclonal AntibodiesIBA 02/2014
1	Glucose (Dextrose)FDA LinkGeneric 11/2013
1	Radioisotopes (Radionuclides)IBA 10/2013
1	Tyrosine Kinase InhibitorsIBA 12/2011
1	fluoromisonidazoleIBA 08/2011
1	ThymidineIBA 03/2011
1	AcidsIBA 08/2010
1	Polyvinyl Chloride (PVC)IBA 01/2010
1	GuanineIBA 05/2009
1	ProdrugsIBA 05/2009
1	9-((2-phosphonylmethoxy)ethyl)guanineIBA 05/2009

Therapy/Procedure

20	Therapeutics 01/2021 - 03/2006
15	Radiotherapy 12/2020 - 06/2005
10	Castration 01/2021 - 05/2013
6	Immunotherapy 01/2021 - 01/2019
6	Drug Therapy (Chemotherapy) 01/2019 - 05/2009
3	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 07/2012 - 06/2003
2	Conformal Radiotherapy 11/2015 - 05/2003
1	Precision Medicine 01/2021
1	Combination Drug Therapy (Combination Chemotherapy) 01/2018
1	Molecular Targeted Therapy 03/2014
1	Animal Assisted Therapy 10/2012
1	Image-Guided Radiotherapy 07/2012
1	Microelectrodes 08/2011